Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Rate of progression differs in frontotemporal dementia and Alzheimer disease

Rascovsky, K., Salmon, D. P., Lipton, A. M., Leverenz, J. B., DeCarli, C., Jagust, W. J., Clark, C. M., Mendez, M. F., Tang-Wai, D. F., Graff-Radford, N. R., Galasko, D. · 2005 · Neurology

Abstract

OBJECTIVE: To compare survival and rates of cognitive and functional decline in patients with autopsy-confirmed frontotemporal dementia (FTD) and Alzheimer disease (AD) in a large multicenter study. BACKGROUND: Despite advances in the clinical characterization of FTD, little is known about its rate of progression. Characterizing survival and rate of decline in FTD is important because it can provide prognostic guidelines and benchmarks to use in the evaluation of disease-modifying drugs. METHODS: Seventy patients with FTD and 70 patients with AD who were followed by seven Alzheimer disease research centers until confirmation of diagnosis at autopsy were matched for overall age, education, and Mini-Mental State Examination (MMSE) score at initial evaluation. Survival and rates of cognitive and functional decline were compared. RESULTS: Patients with FTD had significantly shorter survival from initial evaluation to death than patients with AD (FTD = 4.2 years, AD = 6.0 years; log-rank test = 5.17, p < 0.05), and they declined significantly faster over one year on the MMSE (mean annual rate of change: -6.7 points for FTD vs -2.3 points for AD). A significantly greater proportion of patients with FTD were impaired in basic activities of daily living (ADLs) at initial evaluation, and lost the capacity for independent or minimally-assisted ADLs over the subsequent year. CONCLUSIONS: The results are consistent with shorter survival and faster rates of cognitive and functional decline in patients with frontotemporal dementia (FTD) compared to those with Alzheimer disease (AD). This suggests that FTD follows a more malignant disease course than AD once dementia is clinically recognized.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000171343.43314.6e

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 184

Metadata

Authors
Rascovsky, K., Salmon, D. P., Lipton, A. M., Leverenz, J. B., DeCarli, C., Jagust, W. J., Clark, C. M., Mendez, M. F., Tang-Wai, D. F., Graff-Radford, N. R., & Galasko, D.
Venue
Neurology
Published
2005-08-09
Volume
65
Issue
3
Pages
397-403
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W1986452225
Cited by
184
References
4
FWCI
7.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rate of progression differs in frontotemporal dementia and Alzheimer disease. https://app.cochat.ai/papers/10.1212/01.wnl.0000171343.43314.6e
The paper
Rascovsky, K., Salmon, D. P., Lipton, A. M., Leverenz, J. B., DeCarli, C., Jagust, W. J., Clark, C. M., Mendez, M. F., Tang-Wai, D. F., Graff-Radford, N. R., & Galasko, D. (2005). Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology. https://doi.org/10.1212/01.wnl.0000171343.43314.6e

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.